Zhao Jing, Yan Hui-min, Li Ya, Wang Jia, Han Lu, Wang Zhi-hao, Tang Meng-xiong, Zhang Wei, Zhang Yun, Zhong Ming
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital of Shandong University, Ji'nan 250012, China; Department of Cardiology, Qilu Hospital of Shandong University, Ji'nan 250012, China; Department of Cardiology, Longfu Hospital of Dongcheng District, Beijing 100010, China; Department of Geriatrics, Qilu Hospital of Shandong University, Ji'nan 250012, China; Department of Emergency, Qilu Hospital of Shandong University, Ji'nan 250012, China.
J Zhejiang Univ Sci B. 2015 May;16(5):380-7. doi: 10.1631/jzus.B1400181.
Statins have proven efficacy in inhibiting the onset and progress of atherosclerosis. The effectiveness of pitavastatin in reversing carotid atherosclerosis associated with hypercholesterolemia (HC) is unknown.
To explore the simultaneous effects of pitavastatin calcium on brachial arterial flow-mediated vasodilatation (FMD), carotid intima-media thickness (IMT), and arterial stiffness (β), three surrogate markers of atherosclerosis were studied in HC patients.
A randomized, double-blind trial was performed with 40 HC subjects who fulfilled the inclusion/exclusion criteria. Patients were given pitavastatin calcium 1 mg/d (Group 1) or 2 mg/d (Group 2) for 8 weeks. There were 20 patients in each group, and 30 gender- and age-matched healthy subjects as controls were recruited. FMD of the brachial artery, carotid IMT, and arterial stiffness indicated by β were measured at baseline and at 8 weeks after starting pitavastatin calcium therapy using ultrasound techniques. Biochemical tests were also made on all subjects.
At baseline, higher total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), reduced FMD, and increased β and IMT were observed in HC patients (P<0.001 for all) compared with controls. After 8 weeks, TC was decreased by 20.59%/27.56% and LDL-C 30.92%/35.64%, respectively, in comparison to baseline groups; the HC groups had reduced β and improved endothelial function over the 8-week follow-up (P<0.05-0.001); nonetheless, no significant alterations of IMT were found (P>0.05). Significant negative interactions between TC/LDL and FMD (P<0.05-0.001), positive interactions between TC and IMT (P=0.003) and between TC/LDL and β (P<0.001-0.000) were found.
Treatment with pitavastatin calcium exerted favorable effects on endothelial function and arterial stiffness. It also improved carotid atherosclerosis in patients with HC.
他汀类药物已被证实具有抑制动脉粥样硬化发生和发展的功效。匹伐他汀在逆转与高胆固醇血症(HC)相关的颈动脉粥样硬化方面的有效性尚不清楚。
为研究匹伐他汀钙对肱动脉血流介导的血管舒张功能(FMD)、颈动脉内膜中层厚度(IMT)和动脉僵硬度(β)这三个动脉粥样硬化替代指标的同时影响,对HC患者进行了研究。
对40名符合纳入/排除标准的HC受试者进行了一项随机双盲试验。患者分别给予1mg/d匹伐他汀钙(第1组)或2mg/d匹伐他汀钙(第2组),持续8周。每组有20名患者,并招募了30名年龄和性别匹配的健康受试者作为对照。在基线时以及开始匹伐他汀钙治疗8周后,使用超声技术测量肱动脉的FMD、颈动脉IMT以及由β表示的动脉僵硬度。还对所有受试者进行了生化检测。
在基线时,与对照组相比,HC患者的总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)更高,FMD降低,β和IMT增加(所有P<0.001)。8周后,与基线组相比,TC分别降低了20.59%/27.56%,LDL-C降低了30.92%/35.64%;在8周的随访中,HC组的β降低,内皮功能得到改善(P<0.05 - 0.001);然而,未发现IMT有显著变化(P>0.05)。发现TC/LDL与FMD之间存在显著负相关(P<0.05 - 0.001),TC与IMT之间以及TC/LDL与β之间存在正相关(P = 0.003;P<0.001 - 0.000)。
匹伐他汀钙治疗对内皮功能和动脉僵硬度产生了有益影响。它还改善了HC患者的颈动脉粥样硬化。